beta-3 Adrenergic R/ADRB3 Antibody (493324) [CoraFluor™ 1]

• Reactivity: Hu
• Applications: Flow, ICC/IF
• Clone: 493324
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: CoraFluor 1

beta-3 Adrenergic R/ADRB3 Antibody (493324) [CoraFluor™ 1] Summary

• Description: CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
• Immunogen: Human embryonic kidney cell line HEK293-derived transfected with human beta -3 Adrenergic R/ADRB3
  Met1-Ser408
  Accession # P13945
• Specificity: Stains human beta -3 Adrenergic R/ADRB3 transfectants but not irrelevent transfectants in flow cytometry.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunocytochemistry
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark. Do not freeze.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein A or G purified

Notes

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

Alternate Names for beta-3 Adrenergic R/ADRB3 Antibody (493324) [CoraFluor™ 1]

• ADRB3
• ADRB3R
• adrenergic, beta-3-, receptor
• B3AR
• beta-3 Adrenergic R
• beta-3 adrenergic receptor
• beta3 AdrenergicR
• beta-3 AdrenergicR
• Beta-3 adrenoceptor
• Beta-3 adrenoreceptor
• BETA3AR
• FLJ99960

Background

The Beta-3 Adrenoceptor (ADRB3) is an Adrenergic Receptor that stimulates lipolysis and increases fatty acids in the blood. Stimulation of the beta-3 adrenoceptor leads to lipolysis in white adipocytes and nonshivering thermogenesis in brown fat. The beta-3 adrenoceptor has also been suggested to affect the physiological control of cardiac and vascular contractility; beta-3 adrenoceptor stimulation decreases cardiac contractility through activation of a nitric oxide synthase pathway. A variant of the beta-3 adrenoceptor, Trp64Arg, has been shown to be associated with weight gain (obesity) and susceptibility to non-insulin-dependent diabetes mellitus (NIDDM), but not with coronary artery disease. Trp64Arg variant receptor has been shown to predict a greater tendency to develop abdominal adiposity and high blood pressure with advancing age. ADRB3 has been suggested to be responsible for the negative inotropic effects of catecholamines and may be involved in pathophysiological mechanisms leading to heart failure; ADRB3 is also one of the molecular targets under active research in the treatment of obeisity. Beta-3 adrenoceptor expression has been documented in adipose, heart, and in smooth muscle of digestive and urinary tract organs (bladder, colon, small intestine, stomach, ureter). Utilization of alternate promoters and/or 3-prime untranslated regions may result in tissue-specific regulation of the expression of ADRB3. ESTs have been isolated from heart/melanocyte/uterus and placenta libraries.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.